Sociedad Química y Minera de Chile S.A. (SQM) Forms $58.39 Double Top; Argos Therapeutics (ARGS) Sellers Increased By 25.25% Their Shorts

February 25, 2018 - By Henry Gaston

Sociedad Química y Minera de Chile S.A. (SQM) formed double top with $60.73 target or 4.00% above today’s $58.39 share price. Sociedad Química y Minera de Chile S.A. (SQM) has $15.37B valuation. The stock increased 3.40% or $1.92 during the last trading session, reaching $58.39. About 1.09 million shares traded. Sociedad Química y Minera de Chile S.A. (NYSE:SQM) has risen 69.80% since February 25, 2017 and is uptrending. It has outperformed by 53.10% the S&P500.

Argos Therapeutics Inc (NASDAQ:ARGS) had an increase of 25.25% in short interest. ARGS’s SI was 235,600 shares in February as released by FINRA. Its up 25.25% from 188,100 shares previously. With 1.13 million avg volume, 0 days are for Argos Therapeutics Inc (NASDAQ:ARGS)’s short sellers to cover ARGS’s short positions. The stock decreased 0.74% or $0.0101 during the last trading session, reaching $1.3499. About 235,708 shares traded. Argos Therapeutics, Inc. (NASDAQ:ARGS) has declined 92.57% since February 25, 2017 and is downtrending. It has underperformed by 109.27% the S&P500.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company has market cap of $8.29 million. The firm develops immunotherapies based on its proprietary technology platform, Arcelis. It currently has negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

Investors sentiment increased to 0.63 in Q3 2017. Its up 0.09, from 0.54 in 2017Q2. It improved, as 13 investors sold Argos Therapeutics, Inc. shares while 6 reduced holdings. 8 funds opened positions while 4 raised stakes. 2.64 million shares or 38.27% more from 1.91 million shares in 2017Q2 were reported. Royal National Bank Of Canada holds 1,651 shares or 0% of its portfolio. Germany-based Deutsche Bancshares Ag has invested 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS). Moreover, Vanguard Grp has 0% invested in Argos Therapeutics, Inc. (NASDAQ:ARGS). Wasatch accumulated 0% or 665,831 shares. Two Sigma Limited invested 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS). Meeder Asset Mngmt reported 11,950 shares. National Bank Of Mellon Corp owns 74,379 shares. Bank & Trust Of America De reported 750 shares or 0% of all its holdings. Hightower Advisors Limited Liability Company has invested 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS). Keybank Natl Association Oh invested 0% of its portfolio in Argos Therapeutics, Inc. (NASDAQ:ARGS). State Street holds 11,900 shares or 0% of its portfolio. The New York-based Millennium Management Ltd has invested 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS). Blackrock reported 7,054 shares. Bnp Paribas Arbitrage has invested 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS). Guggenheim Llc invested 0% of its portfolio in Argos Therapeutics, Inc. (NASDAQ:ARGS).

Among 4 analysts covering Argos Therapeutics (NASDAQ:ARGS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Argos Therapeutics had 6 analyst reports since November 16, 2015 according to SRatingsIntel. JMP Securities maintained the shares of ARGS in report on Wednesday, March 9 with “Market Outperform” rating. The rating was maintained by FBR Capital with “Outperform” on Thursday, August 11. The company was maintained on Monday, November 16 by FBR Capital. The rating was maintained by Needham with “Buy” on Tuesday, November 17. As per Thursday, September 21, the company rating was maintained by Needham. The rating was maintained by Roth Capital with “Buy” on Tuesday, April 19.

Analysts await Sociedad Química y Minera de Chile S.A. (NYSE:SQM) to report earnings on March, 7. They expect $0.42 EPS, up 35.48% or $0.11 from last year’s $0.31 per share. SQM’s profit will be $110.54M for 34.76 P/E if the $0.42 EPS becomes a reality. After $0.43 actual EPS reported by Sociedad Química y Minera de Chile S.A. for the previous quarter, Wall Street now forecasts -2.33% negative EPS growth.